AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Sims Limited
Video analysis: SMSMY
All videosNo video analysis for this stock yet. Request one from our team.
News: SMSMY
Sims Limited (SMSMY) Q4 2026 Earnings Call Transcript
Sims Limited (SMSMY) Q4 2026 Earnings Call Transcript
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Mark Sims as the Company's Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead Candel's commercial strategy and launch readiness for aglatimagene besadenovec (aglatimagene or CAN-2409) in intermediate- to high-risk localized prostate cancer.
Sims Metal Management (SMSMY) Upgraded to Buy: What Does It Mean for the Stock?
Sims Metal Management (SMSMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).